Next Article in Journal
The Impact of Mutant p53 in the Non-Coding RNA World
Next Article in Special Issue
Fluorogenic and Bioorthogonal Modification of RNA Using Photoclick Chemistry
Previous Article in Journal
Why Does Knocking Out NACHO, But Not RIC3, Completely Block Expression of α7 Nicotinic Receptors in Mouse Brain?
Previous Article in Special Issue
A Bioorthogonally Applicable, Fluorogenic, Large Stokes-Shift Probe for Intracellular Super-Resolution Imaging of Proteins
Open AccessArticle

Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours

1
Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, INSERM U1239, DC2N, 76000 Rouen, France
2
EA 4108, Laboratory of Computer Science, Information Processing and Systems (LITIS), team “QuantIF”, Centre Henri Becquerel, 76000 Rouen, France
3
Department of Physiology & Pharmacology, Institute of Sherbrooke, Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC J1H 5N4, Canada
4
Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
*
Author to whom correspondence should be addressed.
Co-last authors.
Biomolecules 2020, 10(3), 471; https://doi.org/10.3390/biom10030471
Received: 11 March 2020 / Revised: 17 March 2020 / Accepted: 18 March 2020 / Published: 19 March 2020
(This article belongs to the Special Issue Novel Approaches in Biomolecule Labeling)
Overexpression of G protein-coupled receptors (GPCRs) in tumours is widely used to develop GPCR-targeting radioligands for solid tumour imaging in the context of diagnosis and even treatment. The human vasoactive neuropeptide urotensin II (hUII), which shares structural analogies with somatostatin, interacts with a single high affinity GPCR named UT. High expression of UT has been reported in several types of human solid tumours from lung, gut, prostate, or breast, suggesting that UT is a valuable novel target to design radiolabelled hUII analogues for cancer diagnosis. In this study, two original urotensinergic analogues were first conjugated to a DOTA chelator via an aminohexanoic acid (Ahx) hydrocarbon linker and then -hUII and DOTA-urantide, complexed to the radioactive metal indium isotope to successfully lead to radiolabelled DOTA-Ahx-hUII and DOTA-Ahx-urantide. The 111In-DOTA-hUII in human plasma revealed that only 30% of the radioligand was degraded after a 3-h period. DOTA-hUII and DOTA-urantide exhibited similar binding affinities as native peptides and relayed calcium mobilization in HEK293 cells expressing recombinant human UT. DOTA-hUII, not DOTA-urantide, was able to promote UT internalization in UT-expressing HEK293 cells, thus indicating that radiolabelled 111In-DOTA-hUII would allow sufficient retention of radioactivity within tumour cells or radiolabelled DOTA-urantide may lead to a persistent binding on UT at the plasma membrane. The potential of these radioligands as candidates to target UT was investigated in adenocarcinoma. We showed that hUII stimulated the migration and proliferation of both human lung A549 and colorectal DLD-1 adenocarcinoma cell lines endogenously expressing UT. In vivo intravenous injection of 111In-DOTA-hUII in C57BL/6 mice revealed modest organ signals, with important retention in kidney. 111In-DOTA-hUII or 111In-DOTA-urantide were also injected in nude mice bearing heterotopic xenografts of lung A549 cells or colorectal DLD-1 cells both expressing UT. The observed significant renal uptake and low tumour/muscle ratio (around 2.5) suggest fast tracer clearance from the organism. Together, DOTA-hUII and DOTA-urantide were successfully radiolabelled with 111Indium, the first one functioning as a UT agonist and the second one as a UT-biased ligand/antagonist. To allow tumour-specific targeting and prolong body distribution in preclinical models bearing some solid tumours, these radiolabelled urotensinergic analogues should be optimized for being used as potential molecular tools for diagnosis imaging or even treatment tools. View Full-Text
Keywords: 111Indium-DOTA-peptide analogues; urotensin II; UT receptor; carcinoma; radiolabelling 111Indium-DOTA-peptide analogues; urotensin II; UT receptor; carcinoma; radiolabelling
Show Figures

Graphical abstract

MDPI and ACS Style

Poret, B.; Desrues, L.; Bonin, M.-A.; Pedard, M.; Dubois, M.; Leduc, R.; Modzelewski, R.; Decazes, P.; Morin, F.; Vera, P.; Castel, H.; Bohn, P.; Gandolfo, P. Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours. Biomolecules 2020, 10, 471. https://doi.org/10.3390/biom10030471

AMA Style

Poret B, Desrues L, Bonin M-A, Pedard M, Dubois M, Leduc R, Modzelewski R, Decazes P, Morin F, Vera P, Castel H, Bohn P, Gandolfo P. Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours. Biomolecules. 2020; 10(3):471. https://doi.org/10.3390/biom10030471

Chicago/Turabian Style

Poret, Benjamin; Desrues, Laurence; Bonin, Marc-André; Pedard, Martin; Dubois, Martine; Leduc, Richard; Modzelewski, Romain; Decazes, Pierre; Morin, Fabrice; Vera, Pierre; Castel, Hélène; Bohn, Pierre; Gandolfo, Pierrick. 2020. "Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours" Biomolecules 10, no. 3: 471. https://doi.org/10.3390/biom10030471

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop